Teva’s Baeder: We Need To ‘Crack The Nut’ Of Complex Generics
US Generics Division COO Says Optimum Environment Needs To Be Created
Industry and regulators need to collaborate to provide complex generics with the opportunity to build even further on the significant contributions already made by off-patent medicines to savings and access, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the first part of an exclusive interview.
